Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Technische Universität Dresden
University of Michigan Rogel Cancer Center
Amgen
OHSU Knight Cancer Institute
University of Washington